A fetus with mitochondrial trifunctional protein deficiency: Elevation of 3-OH-acylcarnitines in amniotic fluid functionally assured the genetic diagnosis

Ryosuke Bo a,b,⁎,1, Yuki Hasegawa a, Kenji Yamada a, Hironori Kobayashi a, Takeshi Takedani a, Seiji Fukuda a, Seiji Yamaguchi a

a Department of Pediatrics, Shimane University Faculty of Medicine, 89-1, Ennya-cho, Izumo, Shimane 6938501, Japan
b Department of Pediatrics, Kobe University Graduate School of Medicine, 7-5-1, Kusunokicho, Chuo, Kobe, Hyogo 6500017, Japan

⁎ Corresponding author at: Department of Pediatrics, Shimane University Faculty of Medicine, 89-1, Ennya-cho, Izumo, Shimane 6938501, Japan.
E-mail address: ryobo@med.shimane-u.ac.jp (R. Bo).

1 Present/permanent address: Kobe University Graduate School of Medicine, 7-5-1, Kusunokicho, Chuo, Kobe, Hyogo 6500017, Japan.

Article history:
Received 22 October 2015
Received in revised form 25 November 2015
Accepted 25 November 2015
Available online 5 December 2015

Abstract

Mitochondrial trifunctional protein (TFP) is a multienzyme complex that catalyzes the last three steps of the β-oxidation cycle of long-chain fatty acids. In the prenatal diagnosis of TFP deficiency, acylcarnitine (AC) analysis has been considered difficult because of limited excretion of long-chain ACs into the fetal urine and hence into the amniotic fluid. Here, we report our experience with prenatally diagnosing TFP deficiency using AC analysis of amniotic fluid. The index case was a boy born at 38 weeks gestation and weighing 2588 g. He suddenly became unconscious and hypoglycemic and died on day 6 of life. Postmortem blood AC analysis and gene sequencing revealed TFP deficiency. Therefore, the parents underwent prenatal diagnoses for their subsequent 2 pregnancies. Mutation analysis suggested that one (Case 1) was affected and the other (Case 2) was not. AC analysis also demonstrated identical results, with significantly elevated 3-hydroxy-AC levels in the amniotic fluid of the affected pregnancy compared with those of heterozygotes and normal controls (n = 2 for heterozygotes and n = 8 for normal controls). Our findings suggest that AC analysis can functionally confirm results even in families with unidentified mutations, without raising issues related to maternal cell contamination. During prenatal diagnosis, misdiagnosis has to be avoided, and combining AC analysis with gene sequencing may result in more accurate prenatal diagnosis of TFP deficiency.

© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Mitochondrial trifunctional protein (TFP) is a multienzyme complex consisting of trans-2,3-long-chain enoyl-CoA hydratase (LCEH, EC 4.2.1.74), long-chain 3-OH-acyl-CoA dehydrogenase (LCHAD, EC 1.1.1.211) located in the TFP α-subunit (HADHA, OMIM: 600890), and long-chain 3-ketoacyl-CoA thiolase (LCKT, EC 2.3.1.16) located in the TFP β-subunit (HADHB, OMIM: 143450). These enzymes catalyze the last three steps of the β-oxidation cycle of long-chain fatty acids [1,2]. TFP deficiency is clinically classified into three types: 1) lethal type (neonatal-onset form), which includes the development of profound hypoglycemia, lactic acidosis and cardiomyopathy during the neonatal period; 2) intermediate type (infant-onset form), which is accompanied by hypoketotic hypoglycemia that is generally observed following infection or long periods of fasting during the infancy period; and 3) myopathic type (adult-onset form), which includes muscular symptoms, such as intermittent myalgia or rhabdomyolysis, that are associated with prolonged exercise after adolescence. The neonatal form is normally lethal during the neonatal period, irrespective of any intensive treatments [3]. Therefore, families who have had such an affected child often undergo genetic counseling for prenatal diagnosis during subsequent pregnancies.

TFP deficiency is usually diagnosed based on increased levels of long-chain 3-OH-acylcarnitines (3-OH-ACs), such as C16:OH or C18:1-OH, which can be measured by blood acylcarnitine (AC) analysis using tandem mass spectrometry (MS/MS). However, instead of AC analysis, gene analysis is usually performed for the prenatal diagnosis of TFP deficiency [4]. Herein, we report our experience with prenatally diagnosing TFP deficiency using AC analysis and gene analysis. Our data indicate that AC analysis of amniotic fluid is useful for the prenatal diagnosis of TFP deficiency.
2. Materials and methods

The protocol for this study was approved by the Ethical Committee of Shimane University Faculty of Medicine.

2.1. Case

The index case was a boy born at 38 weeks gestation via vaginal delivery and weighing 2588 g. He was the second child of non-consanguineous parents, and his elder brother was healthy (Fig. 1).

His mother had no abnormalities during the pregnancy, including no HELLP (hemolysis, elevated liver enzymes, and low platelet counts) syndrome or AFLP (acute fatty liver of pregnancy). On the 2nd day after birth, the boy suddenly became unconscious and hypotonic, accompanied by severe hypoglycemia and lactic acidosis. Despite various treatments, including continuous hemodiafiltration that was performed to address the potential of septic shock, his clinical condition deteriorated, and he died of heart failure on the 6th day. Postmortem blood AC analysis revealed the accumulation of 3-OH-ACs, suggesting that the boy had the lethal type of TFP deficiency. Gene analysis and Western blotting confirmed the diagnosis. Therefore, the parents underwent prenatal diagnoses for their subsequent 2 pregnancies (Cases 1 and 2).

After obtaining informed consent from the parents, AC analysis of the amniotic fluid was performed as well as gene analysis and Western blotting.

2.2. Amniotic fluid

Amniotic fluid was collected at 16 and 18 weeks of gestation for Cases 1 and 2, respectively. For comparison purposes, amniotic fluid samples were obtained after 15 weeks from 8 normal controls and from 2 heterozygotes for TFP deficiency who had both undergone prenatal genetic testing (heterozygote-A: c.442+614 A>G and heterozygote-B: c.1364T>N in the HADHB gene).

2.3. Gene analysis

Genomic DNA was extracted from the pellets of centrifuged amniotic fluid using the QIAamp DNA Micro Kit (Qiagen GmbH, Hilden, Germany). Both the HADHA and the HADHB genes, which encode TFP, were sequenced as previously reported [5].

3. Results

3.1. Gene analysis

Direct DNA sequencing of the index case revealed the compound heterozygote mutations c.1392+1G>A and c.1689+2T>N in the HADHA gene, both of which induce mRNA splicing errors. The same mutations were identified in Case 1, whereas no mutations were identified in Case 2.

3.2. Western blot analysis

Western blot analysis of the cultured fibroblasts or amniocytes was performed using a rabbit polyclonal antibody raised against both the α- and β-subunits of TFP; this antibody was kindly provided by Dr. T. Hashimoto, Professor Emeritus, Shinshu University, Matsumoto, Japan. The signals were visualized using the ImmunoPure NBT/BCIP Substrate Kit™ (Promega, Madison, WI, USA), as previously described [6].

2.4. Western blot analysis

Western blot analysis of cultured fibroblasts or amniocytes was performed using a rabbit polyclonal antibody raised against both the α- and β-subunits of TFP; this antibody was kindly provided by Dr. T. Hashimoto, Professor Emeritus, Shinshu University, Matsumoto, Japan. The signals were visualized using the ImmunoPure NBT/BCIP Substrate Kit™ (Promega, Madison, WI, USA), as previously described [6].

3.3. Acylcarnitine analysis

AC analysis of the amniotic fluid of Case 1 demonstrated significant elevations of 3-hydroxy-ACs: C14-OH measured at 55 nmol/L (control, 3.9 ± 5.0; +10.3 SD), C16-OH measured at 120 nmol/L (control, 0.8 ± 1.5; +77.6 SD), C18-OH measured at 31 nmol/L (control, 3.2 ± 5.0; +203.1 SD).

3.4. Acylcarnitine analysis

Western blot analysis of cultured fibroblasts or amniocytes was performed using a rabbit polyclonal antibody raised against both the α- and β-subunits of TFP; this antibody was kindly provided by Dr. T. Hashimoto, Professor Emeritus, Shinshu University, Matsumoto, Japan. The signals were visualized using the ImmunoPure NBT/BCIP Substrate Kit™ (Promega, Madison, WI, USA), as previously described [6].

Fig. 1. Family tree. The age of each patient and sibling is described for the time at which the amniotic fluid of Case 2 was obtained.
amniotic fluid has been reported [8–11]. In contrast, the prenatal diagnosis of long-chain fatty acid oxidation disorders (FAODs) using MS/MS has not been considered as an optimal approach because ACs derived from long-chain fatty acids do not seem to accumulate in the fetus in response to the inhibition of β-oxidation via malonyl-CoA-mediated suppression of carnitine palmitoyltransferase (CPT)-1 activity and seem to have limited excretion into the fetal urine and hence into the amniotic fluid due to poor solubility [12,13].

However, a recent report demonstrated that fatty acid oxidation is activated and plays a significant role even during the fetal periods [14–16], suggesting that the potential use of AC analysis to detect fetal FAODs is feasible. Although long-chain ACs are considered to be hydrophobic, the presence of a polar hydroxyl group can make ACs (C14:1, C16–OH, C18:1–OH) more soluble in amniotic fluid, thus making their detection in amniotic fluid feasible. Moreover, as identified in Case 1, unsaturated ACs such as C14:1 were elevated. Although it has been suggested that AC analysis using MS/MS is not appropriate for the prenatal diagnosis of long-chain FAODs, the results presented here show that ACs specific for other long-chain FAODs, such as VLCAD deficiency, could be detected during the prenatal period.

AC analysis of amniotic fluid has several advantages over gene analysis and Western blotting. AC analysis allows for the rapid detection of accumulated ACs in a small volume of amniotic fluid. Moreover, this analysis makes prenatal diagnosis feasible, even when the mutation of the index case cannot be identified and there are no issues related to contamination by maternal cells, in contrast to gene analysis. In our study, the AC values overlapped between heterozygotes and normal controls, although those with affected specimens were undoubtedly distinguishable from the heterozygotes and the controls. These findings suggest that the accurate diagnosis of milder cases may be complicated, although prenatal diagnosis may not be necessary in these cases.

Because only one case was studied in this report, additional studies need to be performed. Nevertheless, our study demonstrates that AC analysis can be used for prenatal diagnosis of TFP deficiency.

5. Conclusion

During prenatal diagnosis, misdiagnosis has to be avoided in all cases. Therefore, multiple approaches from several angles are desirable, and their results should be evaluated comprehensively. In this regard, combining AC analysis with genetic testing (gene sequencing) may result in more effective prenatal diagnoses of TFP deficiency and may avoid misleading results.

Acknowledgments

We thank Ms. M. Furui, N. Tomita, Y. Ito, T. Esumi and E. Mizuno from the Department of Pediatrics, Shimane University, for their technical assistance. Furthermore, we greatly appreciate the support offered by Dr. Keisuke Sato from Shizuoka Children’s Hospital, and we thank Toru Otabe, from the Otabe Obstetrical and Gynecological Clinic, for providing clinical information. Lastly, we thank Dr. Takashi Hashimoto, Professor Emeritus of Shinsyu University, Japan, for kindly providing the antibody against TFP.

References

[1] Y. Uchida, K. Iizai, T. Orii, T. Hashimoto, Novel fatty acid-β-oxidation enzymes in rat liver mitochondria: II. Purification and properties of enoyl-coenzyme A (CoA) hydratase/3-hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase trifunctional protein, J. Biol. Chem. 267 (1992) 1034–1041.
[2] S. Ushikubo, T. Aoyama, T. Kamijo, R.J. Wanders, P. Rinaldo, J. Vockley, et al., Molecular characterization of mitochondrial trifunctional protein deficiency: formation of the enzyme complex is important for stabilization of both alpha- and beta-subunits, Am. J. Hum. Genet. 58 (1996) 979–988.
[3] U. Spiekerkoetter, Z. Khchoua, Z. Yue, A.W. Strauss, The early-onset phenotype of mitochondrial trifunctional protein deficiency: a lethal disorder with multiple tissue involvement; J. Inherit. Metab. Dis. 27 (2004) 294–296.
[4] J.A. Ibdah, Y. Zhao, J. Viola, B. Gibson, M.J. Bennett, A.W. Strauss, Molecular prenatal diagnosis in families with fetal mitochondrial trifunctional protein mutations, J. Pediatr. 138 (2001) 396–399.

[5] J. Purevsuren, T. Fukao, Y. Hasegawa, S. Fukuda, H. Kobayashi, S. Yamaguchi, Study of deep intronic sequence exonization in a Japanese neonate with a mitochondrial trifunctional protein deficiency, Mol. Genet. Metab. 95 (2008) 46–51.

[6] J. Purevsuren, T. Fukao, Y. Hasegawa, H. Kobayashi, H. Li, Y. Mushimoto, et al., Clinical and molecular aspects of Japanese patients with mitochondrial trifunctional protein deficiency, Mol. Genet. Metab. 98 (2009) 372–377.

[7] H. Kobayashi, Y. Hasegawa, M. Endo, J. Purevsuren, S. Yamaguchi, ESI–MS/MS study of acylcarnitine profiles in urine from patients with organic acidemias and fatty acid oxidation disorders, J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 855 (2007) 80–87.

[8] Y. Hasegawa, M. Iga, M. Kimura, Y. Shigematsu, S. Yamaguchi, Prenatal diagnosis for organic acid disorders using two mass spectrometric methods, gas chromatography mass spectrometry and tandem mass spectrometry, J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 823 (2005) 13–17.

[9] S.I. Goodman, D.A. Gallegos, C.J. Pullin, B. Halpern, R.J. Truscott, G. Wise, et al., Antenatal diagnosis of glutaric acidemia, Am. J. Hum. Genet. 32 (1980) 695–699.

[10] J.L. Van Hove, D.H. Chace, S.G. Kahler, D.S. Millington, Acylcarnitines in amniotic fluid: application to the prenatal diagnosis of propionic acidemia, J. Inherit. Metab. Dis. 16 (1993) 361–367.

[11] D. Penn, E. Schmidt-Sommerfeld, C. Jakobs, L.L. Bieber, Amniotic fluid propionylcarnitine in methylmalonic aciduria, J. Inherit. Metab. Dis. 10 (1987) 376–382.

[12] S. Eaton, Control of mitochondrial beta-oxidation flux, Prog. Lipid Res. 41 (2002) 197–239.

[13] F. Boemer, M. Deberg, R. Schoos, J.-H. Caberg, S. Gaillez, C. Dugaquier, et al., Diagnostic pitfalls in antenatal manifestations of CPT II deficiency, Clin. Genet. (2015) (in press).

[14] D. Rakheja, M.J. Bennett, B.M. Foster, R. Domiati-Saad, B.B. Rogers, Evidence for fatty acid oxidation in human placenta, and the relationship of fatty acid oxidation enzyme activities with gestational age, Placenta 23 (2002) 447–450.

[15] N.A. Oey, J.P. Ruiter, T. Attié-Bitach, L. IJlst, R.J. Wanders, F.A. Wijburg, Fatty acid oxidation in the human fetus: implications for fetal and adult disease, J. Inherit. Metab. Dis. 29 (2006) 71–75.

[16] U. Spiekerkoetter, M. Mueller, E. Cloppenburg, R. Motz, E. Mayatepek, B. Bueltmann, et al., Intrauterine cardiomyopathy and cardiac mitochondrial proliferation in mitochondrial trifunctional protein (TFP) deficiency, Mol. Genet. Metab. 94 (2008) 428–430.